Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 clinical development for the treatment of diabetes; and LX9211 that is in Phase 1 clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone281-863-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$63.21 million
Profitability
Miscellaneous
Employees174
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Lexicon Pharmaceuticals (NASDAQ:LXRX) Frequently Asked Questions
What is Lexicon Pharmaceuticals' stock symbol?
Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."
How were Lexicon Pharmaceuticals' earnings last quarter?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Wednesday, March, 13th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.12. The biopharmaceutical company had revenue of $17.10 million for the quarter, compared to analysts' expectations of $13.33 million. Lexicon Pharmaceuticals had a negative return on equity of 1,247.65% and a negative net margin of 192.53%. The firm's revenue was down 49.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.27) earnings per share. View Lexicon Pharmaceuticals' Earnings History.
When is Lexicon Pharmaceuticals' next earnings date?
What price target have analysts set for LXRX?
6 analysts have issued 1 year target prices for Lexicon Pharmaceuticals' shares. Their forecasts range from $14.00 to $38.00. On average, they anticipate Lexicon Pharmaceuticals' stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 220.5% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.
What is the consensus analysts' recommendation for Lexicon Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.
Has Lexicon Pharmaceuticals been receiving favorable news coverage?
News headlines about LXRX stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lexicon Pharmaceuticals earned a media sentiment score of -1.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near future.
Who are some of Lexicon Pharmaceuticals' key competitors?
Some companies that are related to Lexicon Pharmaceuticals include Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Reata Pharmaceuticals (RETA), Akcea Therapeutics (AKCA), Mirati Therapeutics (MRTX), Ligand Pharmaceuticals (LGND), Emergent Biosolutions (EBS), Uniqure (QURE), Insmed (INSM), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA), Biohaven Pharmaceutical (BHVN) and Myokardia (MYOK).
What other stocks do shareholders of Lexicon Pharmaceuticals own?
Who are Lexicon Pharmaceuticals' key executives?
Lexicon Pharmaceuticals' management team includes the folowing people:
- Mr. Lonnel Coats, Pres, CEO & Director (Age 54)
- Mr. Jeffrey L. Wade, Exec. VP of Corp. & Admin. Affairs and CFO (Age 54)
- Dr. Pablo Lapuerta, Exec. VP & Chief Medical Officer (Age 56)
- Dr. Praveen Tyle, Exec. VP of R&D (Age 59)
- Mr. Alexander A. Santini, Exec. VP & Chief Commercial Officer (Age 60)
Who are Lexicon Pharmaceuticals' major shareholders?
Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (13.91%), BlackRock Inc. (4.11%), Northern Trust Corp (0.57%), Geode Capital Management LLC (0.53%), Geode Capital Management LLC (0.53%) and Pinnacle Associates Ltd. (0.51%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, James F Tessmer, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.
Which institutional investors are selling Lexicon Pharmaceuticals stock?
LXRX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, First Trust Advisors LP, BlackRock Inc., Stifel Financial Corp, Pinnacle Associates Ltd., Bank of America Corp DE and GSA Capital Partners LLP. View Insider Buying and Selling for Lexicon Pharmaceuticals.
Which institutional investors are buying Lexicon Pharmaceuticals stock?
LXRX stock was purchased by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Norges Bank, Two Sigma Investments LP, Fosun International Ltd, Royal London Asset Management Ltd., Wedbush Securities Inc., Squarepoint Ops LLC and Virtus ETF Advisers LLC. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Jeffrey L Wade, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.
How do I buy shares of Lexicon Pharmaceuticals?
Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Lexicon Pharmaceuticals' stock price today?
One share of LXRX stock can currently be purchased for approximately $7.80.
How big of a company is Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals has a market capitalization of $828.91 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 174 workers across the globe.
What is Lexicon Pharmaceuticals' official website?
How can I contact Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.
MarketBeat Community Rating for Lexicon Pharmaceuticals (NASDAQ LXRX)
MarketBeat's community ratings are surveys of what our community members think about Lexicon Pharmaceuticals and other stocks. Vote "Outperform" if you believe LXRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LXRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
